Table 2.

Down-regulation of HDACs by inhibitors of the mevalonic acid pathway^a

Gene expression	U2-Ibn	MG-Ibn	PC-Ibn	MDA-Ibn	U2-Sim	MG-Sim	PC-Sim	MDA-Sim	HMC-Sim
HDAC1 basal expression	10.9	10.2	12.2	10.0	10.5	10.2	11.0	10.0	10.2
HDAC1 treated expression	10.8	9.9	11.9	9.9	10.7	10.1	10.1	9.7	9.4
HDAC1 fold expression	−1.10∗	−1.28∗	−1.21∗	−1.14∗	1.11†	−1.07∗	−1.85∗	−1.31∗	−1.69∗
HDAC2 basal expression	10.5	4.6	10.6	8.4	10.5	4.6	8.4	4.3	7.9
HDAC2 treated expression	10.0	4.5	10.0	8.3	10.4	4.6	8.0	4.5	7.0
HDAC2 fold expression	−1.38∗	−1.07∗	−1.44∗	−1.14∗	−1.06∗	1.04†	−1.30∗	1.19†	−1.84∗
HDAC3 basal expression	10.7	9.8	10.9	9.9	10.4	9.8	10.0	9.9	9.8
HDAC3 treated expression	10.2	9.4	10.6	10.1	10.6	9.6	9.6	9.9	9.3
HDAC3 fold expression	−1.40∗	−1.33∗	−1.26∗	1.09†	1.13†	−1.20∗	−1.30∗	−1.00	−1.26∗
HDAC7 basal expression	9.1	9.3	8.8	9.1	9.1	9.3	9.3	9.1	9.1
HDAC7 treated expression	8.8	9.2	8.6	9.2	9.0	9.5	8.9	9.0	9.0
HDAC7 fold expression	−1.28∗	−1.13∗	−1.14∗	1.03†	−1.09∗	1.08†	−1.34∗	−1.08∗	−1.08∗
HDAC8 basal expression	9.7	8.1	9.8	8.0	9.7	8.1	8.1	8.0	8.7
HDAC8 treated expression	9.1	7.4	9.6	8.1	9.7	7.8	8.1	7.7	8.7
HDAC8 fold expression	−1.49∗	−1.68∗	−1.14∗	1.03†	−1.02	−1.25∗	−1.01	−1.28∗	−1.05∗

Abbreviations: HMC, HMC1.1 mast cell line; U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA-MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; HMC, HMC1.1 mast cell line; Ibn, ibandronate; Sim, simvastatin; C75, inhibitor of fatty acid synthase.

^aAll data are derived from Affymetrix ST1.0 expression microarrays, which were used for analysis of mRNA from cell lines after 3 days treatment with respective drugs (150µM ibandronate, 32µM simvastatin, 27µM C75). Expression levels are in relation to the set of standard genes in the microarrays; ^∗ = fold downregulation and † = fold upregulation.